— The Future of Rare at Insmed:
Functional Genes, AI-Enhanced Proteins, Glowing Algae, and
More—
BRIDGEWATER, N.J., April 24,
2023 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical
company on a mission to transform the lives of patients with
serious and rare diseases, today announced that it will host an
investor and analyst event on Monday, May 8, 2023. The event,
titled "The Future of Rare at Insmed: Functional Genes, AI-Enhanced
Proteins, Glowing Algae, and More," will take place from
8:00 a.m. to 12:00 p.m. ET in
New York and will be
simultaneously webcast.
The agenda will include a deep dive into Insmed's early-stage
research programs. Members of the management team will be joined by
Insmed's Deimmunized by Design, gene therapy, and protein
manufacturing team leaders to unveil the platforms and capabilities
that the company believes will generate at least six new
investigational new drug applications by 2025.
A live webcast will be available on the company's website
at www.insmed.com. A replay of the event will be
accessible approximately 30 minutes after its completion. A copy of
the presentation materials and webcast will be archived for 90 days
under the Investor Relations section of the company's website
at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United
States, Europe, and
Japan to treat a chronic,
debilitating lung disease. The Company is also progressing a robust
pipeline of investigational therapies targeting areas of serious
unmet need, including neutrophil-mediated inflammatory diseases and
rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint
across Europe and in Japan. For more information, visit
www.insmed.com.
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-investor-and-analyst-event-on-may-8-2023-301805111.html
SOURCE Insmed Incorporated